255 related articles for article (PubMed ID: 18250496)
1. Prolong QT interval and "torsades de pointes" associated with different group of drugs.
Gongadze N; Kezeli T; Antelava N
Georgian Med News; 2007 Dec; (153):45-9. PubMed ID: 18250496
[TBL] [Abstract][Full Text] [Related]
2. Cardiac K+ channels and drug-acquired long QT syndrome.
Drici MD; Barhanin J
Therapie; 2000; 55(1):185-93. PubMed ID: 10860023
[TBL] [Abstract][Full Text] [Related]
3. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
[TBL] [Abstract][Full Text] [Related]
4. [Molecular genetics of the long QT syndrome: clinical aspects].
Sepp R; Csanády M
Orv Hetil; 1999 Nov; 140(47):2633-8. PubMed ID: 10613047
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced long QT syndrome and torsade de pointes.
Morissette P; Hreiche R; Turgeon J
Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
[TBL] [Abstract][Full Text] [Related]
6. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
Calderone V; Cavero I
Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms and management of congenital and acquired long QT syndromes.
Lazzara R
Arch Mal Coeur Vaiss; 1996 Feb; 89 Spec No 1():51-5. PubMed ID: 8734164
[TBL] [Abstract][Full Text] [Related]
8. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
Shah RR
Novartis Found Symp; 2005; 266():251-80; discussion 280-5. PubMed ID: 16050273
[TBL] [Abstract][Full Text] [Related]
9. Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes.
Sala M; Coppa F; Cappucciati C; Brambilla P; d'Allio G; Caverzasi E; Barale F; De Ferrari GM
Curr Opin Investig Drugs; 2006 Mar; 7(3):256-63. PubMed ID: 16555686
[TBL] [Abstract][Full Text] [Related]
10. [Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia].
Gury C; Canceil O; Iaria P
Encephale; 2000; 26(6):62-72. PubMed ID: 11217540
[TBL] [Abstract][Full Text] [Related]
11. QT interval prolongation, torsade de pointes and renal disease.
Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
[TBL] [Abstract][Full Text] [Related]
12. Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
Keivanidou A; Arnaoutoglou C; Krommydas A; Papanikolaou G; Tsiptses K; Chrisopoulos C; Kirpizidis C
Cardiol J; 2009; 16(2):172-4. PubMed ID: 19387967
[TBL] [Abstract][Full Text] [Related]
13. Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.
Mok NS; Lo YK; Tsui PT; Lam CW
J Cardiovasc Electrophysiol; 2005 Dec; 16(12):1375-7. PubMed ID: 16403073
[TBL] [Abstract][Full Text] [Related]
14. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
Gintant GA; Su Z; Martin RL; Cox BF
Toxicol Pathol; 2006; 34(1):81-90. PubMed ID: 16507548
[TBL] [Abstract][Full Text] [Related]
15. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.
Riera AR; Uchida AH; Ferreira C; Ferreira Filho C; Schapachnik E; Dubner S; Zhang L; Moffa PJ
Cardiol J; 2008; 15(3):209-19. PubMed ID: 18651412
[TBL] [Abstract][Full Text] [Related]
16. Schizophrenia, antipsychotic drugs, and cardiovascular disease.
Glassman AH
J Clin Psychiatry; 2005; 66 Suppl 6():5-10. PubMed ID: 16107178
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced long QT and torsade de pointes: recent advances.
Kannankeril PJ; Roden DM
Curr Opin Cardiol; 2007 Jan; 22(1):39-43. PubMed ID: 17143043
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
Ahmad K; Dorian P
Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
[TBL] [Abstract][Full Text] [Related]
19. Use of in vitro methods to predict QT prolongation.
Hammond TG; Pollard CE
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):446-50. PubMed ID: 16023163
[TBL] [Abstract][Full Text] [Related]
20. Torsade de pointes: the clinical considerations.
Gowda RM; Khan IA; Wilbur SL; Vasavada BC; Sacchi TJ
Int J Cardiol; 2004 Jul; 96(1):1-6. PubMed ID: 15203254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
